CN108472288B - Kv3通道的调节剂用于治疗疼痛 - Google Patents

Kv3通道的调节剂用于治疗疼痛 Download PDF

Info

Publication number
CN108472288B
CN108472288B CN201680072639.8A CN201680072639A CN108472288B CN 108472288 B CN108472288 B CN 108472288B CN 201680072639 A CN201680072639 A CN 201680072639A CN 108472288 B CN108472288 B CN 108472288B
Authority
CN
China
Prior art keywords
methyl
oxy
pain
compound
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680072639.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN108472288A (zh
Inventor
C·拉奇
G·澳瓦罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autifony Therapeutics Ltd
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Priority to CN202410102663.8A priority Critical patent/CN118267386A/zh
Publication of CN108472288A publication Critical patent/CN108472288A/zh
Application granted granted Critical
Publication of CN108472288B publication Critical patent/CN108472288B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/30Compounds having groups
    • C07C43/315Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201680072639.8A 2015-12-10 2016-12-09 Kv3通道的调节剂用于治疗疼痛 Active CN108472288B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410102663.8A CN118267386A (zh) 2015-12-10 2016-12-09 Kv3通道的调节剂用于治疗疼痛

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1521751.6 2015-12-10
GBGB1521751.6A GB201521751D0 (en) 2015-12-10 2015-12-10 Novel uses
PCT/GB2016/053879 WO2017098254A1 (en) 2015-12-10 2016-12-09 Modulators of kv3 channels to treat pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410102663.8A Division CN118267386A (zh) 2015-12-10 2016-12-09 Kv3通道的调节剂用于治疗疼痛

Publications (2)

Publication Number Publication Date
CN108472288A CN108472288A (zh) 2018-08-31
CN108472288B true CN108472288B (zh) 2024-05-28

Family

ID=55274489

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680072639.8A Active CN108472288B (zh) 2015-12-10 2016-12-09 Kv3通道的调节剂用于治疗疼痛
CN202410102663.8A Pending CN118267386A (zh) 2015-12-10 2016-12-09 Kv3通道的调节剂用于治疗疼痛

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410102663.8A Pending CN118267386A (zh) 2015-12-10 2016-12-09 Kv3通道的调节剂用于治疗疼痛

Country Status (21)

Country Link
US (3) US11147813B2 (enExample)
EP (1) EP3386506B1 (enExample)
JP (3) JP7149847B2 (enExample)
KR (1) KR102812887B1 (enExample)
CN (2) CN108472288B (enExample)
AU (1) AU2016367239B2 (enExample)
BR (1) BR112018011700B1 (enExample)
CA (1) CA3005302A1 (enExample)
DK (1) DK3386506T3 (enExample)
EA (1) EA038059B1 (enExample)
ES (1) ES2974902T3 (enExample)
FI (1) FI3386506T3 (enExample)
GB (1) GB201521751D0 (enExample)
HR (1) HRP20240497T1 (enExample)
HU (1) HUE066879T2 (enExample)
IL (1) IL259717B (enExample)
MX (1) MX385578B (enExample)
PL (1) PL3386506T3 (enExample)
PT (1) PT3386506T (enExample)
SG (1) SG11201804123VA (enExample)
WO (1) WO2017098254A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
EP3555073A1 (en) 2016-12-16 2019-10-23 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
WO2018220762A1 (ja) 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
US12358901B2 (en) * 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
HUE068686T2 (hu) * 2018-10-16 2025-01-28 Autifony Therapeutics Ltd Új vegyületek
US20200131156A1 (en) * 2018-10-30 2020-04-30 H. Lundbeck A/S ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS
TWI877067B (zh) 2018-11-30 2025-03-11 日商大塚製藥股份有限公司 雜環化合物
PH12022551955A1 (en) 2020-02-06 2023-10-23 Autifony Therapeutics Ltd Novel compound
AU2022327657A1 (en) 2021-08-10 2024-02-01 Autifony Therapeutics Limited Potassium channel modulators
CN113788741B (zh) * 2021-09-28 2023-12-29 大连九信精细化工有限公司 一种制备2-环丙基苯酚衍生物的方法
WO2024121552A1 (en) 2022-12-06 2024-06-13 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753533A (zh) * 2009-12-11 2012-10-24 奥蒂福尼疗法有限公司 咪唑烷二酮衍生物
WO2013083994A1 (en) * 2011-12-06 2013-06-13 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
CN103328467A (zh) * 2010-12-06 2013-09-25 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
CN104334547A (zh) * 2012-05-22 2015-02-04 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2300426A1 (en) 2008-06-06 2011-03-30 UCB Pharma, S.A. Compounds comprising a cyclobutoxy group
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
US9669030B2 (en) 2012-05-22 2017-06-06 Autifony Therapeutics Limited Hydantoin derivatives as Kv3 inhibitors
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753533A (zh) * 2009-12-11 2012-10-24 奥蒂福尼疗法有限公司 咪唑烷二酮衍生物
CN103328467A (zh) * 2010-12-06 2013-09-25 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
WO2013083994A1 (en) * 2011-12-06 2013-06-13 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
CN104334547A (zh) * 2012-05-22 2015-02-04 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kv7 Channels as Targets for the Treatment of Pain;A.D. Wickenden等;《Current Pharmaceutical Design》;20091231;第15卷(第15期);第1773-1798页 *
电压门控性钾通道与三叉神经痛;李娜 等;《第二军医大学学报》;20090430;第30卷(第4期);第432-436页 *

Also Published As

Publication number Publication date
MX2018007074A (es) 2018-12-12
JP7149847B2 (ja) 2022-10-07
WO2017098254A1 (en) 2017-06-15
CA3005302A1 (en) 2017-06-15
JP2025003958A (ja) 2025-01-14
GB201521751D0 (en) 2016-01-27
AU2016367239A1 (en) 2018-06-07
JP2019506367A (ja) 2019-03-07
BR112018011700A2 (pt) 2018-11-27
PT3386506T (pt) 2024-03-28
US11944623B2 (en) 2024-04-02
CN118267386A (zh) 2024-07-02
BR112018011700B1 (pt) 2023-12-26
US20190000848A1 (en) 2019-01-03
HRP20240497T1 (hr) 2024-08-16
SG11201804123VA (en) 2018-06-28
EA201891377A1 (ru) 2019-01-31
EP3386506B1 (en) 2024-01-24
IL259717B (en) 2021-05-31
AU2016367239B2 (en) 2020-07-09
KR102812887B1 (ko) 2025-05-26
CN108472288A (zh) 2018-08-31
US11147813B2 (en) 2021-10-19
EP3386506A1 (en) 2018-10-17
EA038059B1 (ru) 2021-06-30
MX385578B (es) 2025-03-18
US20220071998A1 (en) 2022-03-10
US20250017925A1 (en) 2025-01-16
PL3386506T3 (pl) 2024-06-03
KR20180097549A (ko) 2018-08-31
HUE066879T2 (hu) 2024-09-28
FI3386506T3 (fi) 2024-04-23
IL259717A (en) 2018-07-31
DK3386506T3 (da) 2024-05-06
ES2974902T3 (es) 2024-07-02
JP2022141699A (ja) 2022-09-29

Similar Documents

Publication Publication Date Title
CN108472288B (zh) Kv3通道的调节剂用于治疗疼痛
EP3390394B1 (en) Hydantoin modulators of kv3 channels
US9669030B2 (en) Hydantoin derivatives as Kv3 inhibitors
WO2013182851A1 (en) Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
JP6337124B2 (ja) インダゾール及びその使用
EP3490977B1 (en) Cyclobutane derivatives as modulators of voltage-gated potassium channels
JP2017503837A (ja) ピリジン類及びピリミジン類並びにその使用
WO2018109484A1 (en) Hydantoin modulators of kv3 channels
KR20180004193A (ko) Gpr52와 관련된 장애의 치료 또는 예방을 위한 gpr52 조절제로서 1-헤테로아릴-인돌린-4-카르복스아미드
TW202031645A (zh) 作為Kv3鉀通道激活劑之芳基磺醯基吡咯甲醯胺衍生物
HK1262362A1 (en) Modulators of kv3 channels to treat pain
HK1262362B (en) Modulators of kv3 channels to treat pain

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant